Literature DB >> 17581991

Expression and characterization of a minimal hepatitis C virus glycoprotein E2 core domain that retains CD81 binding.

Kathleen McCaffrey1, Irene Boo, Pantelis Poumbourios, Heidi E Drummer.   

Abstract

The hepatitis C virus glycoprotein E2 receptor-binding domain is encompassed by amino acids 384 to 661 (E2(661)) and contains two hypervariable sequences, HVR1 and HVR2. E2 sequence comparisons revealed a third variable region, located between residues 570 and 580, that varies widely between genotypes, designated here as igVR, the intergenotypic variable region. A secreted E2(661) glycoprotein with simultaneous deletions of the three variable sequences retained its ability to bind CD81 and conformation-dependent monoclonal antibodies (MAbs) and displayed enhanced binding to a neutralizing MAb directed to E2 immunogenic domain B. Our data provide insights into the E2 structure by suggesting that the three variable regions reside outside a conserved E2 core.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17581991      PMCID: PMC1951388          DOI: 10.1128/JVI.02782-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

Review 1.  NPS@: network protein sequence analysis.

Authors:  C Combet; C Blanchet; C Geourjon; G Deléage
Journal:  Trends Biochem Sci       Date:  2000-03       Impact factor: 13.807

2.  Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment.

Authors:  F Penin; C Combet; G Germanidis; P O Frainais; G Deléage; J M Pawlotsky
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Identification of the hepatitis C virus E2 glycoprotein binding site on the large extracellular loop of CD81.

Authors:  Heidi E Drummer; Kirilee A Wilson; Pantelis Poumbourios
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

4.  Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells.

Authors:  A Wack; E Soldaini; C Tseng; S Nuti; G Klimpel; S Abrignani
Journal:  Eur J Immunol       Date:  2001-01       Impact factor: 5.532

5.  Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.

Authors:  K G Hadlock; R E Lanford; S Perkins; J Rowe; Q Yang; S Levy; P Pileri; S Abrignani; S K Foung
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.

Authors:  Elisa Scarselli; Helenia Ansuini; Raffaele Cerino; Rosa Maria Roccasecca; Stefano Acali; Gessica Filocamo; Cinzia Traboni; Alfredo Nicosia; Riccardo Cortese; Alessandra Vitelli
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

7.  Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2.

Authors:  RosaMaria Roccasecca; Helenia Ansuini; Alessandra Vitelli; Annalisa Meola; Elisa Scarselli; Stefano Acali; Monica Pezzanera; Bruno Bruni Ercole; Jane McKeating; Asutosh Yagnik; Armin Lahm; Anna Tramontano; Riccardo Cortese; Alfredo Nicosia
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

8.  Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry.

Authors:  Matthew J Evans; Thomas von Hahn; Donna M Tscherne; Andrew J Syder; Maryline Panis; Benno Wölk; Theodora Hatziioannou; Jane A McKeating; Paul D Bieniasz; Charles M Rice
Journal:  Nature       Date:  2007-02-25       Impact factor: 49.962

9.  Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein.

Authors:  Stefania Crotta; Annalisa Stilla; Andreas Wack; Annalisa D'Andrea; Sandra Nuti; Ugo D'Oro; Marta Mosca; Franco Filliponi; R Maurizia Brunetto; Ferruccio Bonino; Sergio Abrignani; Nicholas M Valiante
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

10.  Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions.

Authors:  Chien-Te K Tseng; Gary R Klimpel
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

View more
  37 in total

1.  Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature.

Authors:  Michelle C Sabo; Vincent C Luca; Stuart C Ray; Jens Bukh; Daved H Fremont; Michael S Diamond
Journal:  Virology       Date:  2011-11-12       Impact factor: 3.616

2.  Role of conserved cysteine residues in hepatitis C virus glycoprotein e2 folding and function.

Authors:  Kathleen McCaffrey; Irene Boo; Kevin Tewierek; Mark L Edmunds; Pantelis Poumbourios; Heidi E Drummer
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

3.  Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies.

Authors:  Isabel Fofana; Samira Fafi-Kremer; Patric Carolla; Catherine Fauvelle; Muhammad Nauman Zahid; Marine Turek; Laura Heydmann; Karine Cury; Juliette Hayer; Christophe Combet; François-Loïc Cosset; Thomas Pietschmann; Marie-Sophie Hiet; Ralf Bartenschlager; François Habersetzer; Michel Doffoël; Zhen-Yong Keck; Steven K H Foung; Mirjam B Zeisel; Françoise Stoll-Keller; Thomas F Baumert
Journal:  Gastroenterology       Date:  2012-04-10       Impact factor: 22.682

4.  An Optimized Hepatitis C Virus E2 Glycoprotein Core Adopts a Functional Homodimer That Efficiently Blocks Virus Entry.

Authors:  Kathleen McCaffrey; Irene Boo; Catherine M Owczarek; Matthew P Hardy; Matthew A Perugini; Louis Fabri; Pierre Scotney; Pantelis Poumbourios; Heidi E Drummer
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

5.  Contribution of redox status to hepatitis C virus E2 envelope protein function and antigenicity.

Authors:  Emmanuel Fenouillet; Dimitri Lavillette; Silvia Loureiro; George Krashias; Guillemette Maurin; François-Loïc Cosset; Ian M Jones; Rym Barbouche
Journal:  J Biol Chem       Date:  2008-07-30       Impact factor: 5.157

6.  The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule.

Authors:  Thomas Krey; Jacques d'Alayer; Carlos M Kikuti; Aure Saulnier; Laurence Damier-Piolle; Isabelle Petitpas; Daniel X Johansson; Rajiv G Tawar; Bruno Baron; Bruno Robert; Patrick England; Mats A A Persson; Annette Martin; Félix A Rey
Journal:  PLoS Pathog       Date:  2010-02-19       Impact factor: 6.823

Review 7.  HCV E2 core structures and mAbs: something is still missing.

Authors:  Matteo Castelli; Nicola Clementi; Giuseppe A Sautto; Jennifer Pfaff; Kristen M Kahle; Trevor Barnes; Benjamin J Doranz; Matteo Dal Peraro; Massimo Clementi; Roberto Burioni; Nicasio Mancini
Journal:  Drug Discov Today       Date:  2014-08-27       Impact factor: 7.851

8.  A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies.

Authors:  Lisa N Wasilewski; Ramy El-Diwany; Supriya Munshaw; Anna E Snider; Jillian K Brady; William O Osburn; Stuart C Ray; Justin R Bailey
Journal:  J Virol       Date:  2016-01-27       Impact factor: 5.103

9.  Disulfide bonds in hepatitis C virus glycoprotein E1 control the assembly and entry functions of E2 glycoprotein.

Authors:  Ahmed Wahid; François Helle; Véronique Descamps; Gilles Duverlie; François Penin; Jean Dubuisson
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

10.  Full-length characterization of hepatitis C virus subtype 3a reveals novel hypervariable regions under positive selection during acute infection.

Authors:  Isla Humphreys; Vicki Fleming; Paolo Fabris; Joe Parker; Bodo Schulenberg; Anthony Brown; Charis Demetriou; Silvana Gaudieri; Katja Pfafferott; Michaela Lucas; Jane Collier; Kuan-Hsiang Gary Huang; Oliver G Pybus; Paul Klenerman; Eleanor Barnes
Journal:  J Virol       Date:  2009-09-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.